Importantly, combination therapy led to greater expansion of P14s in both tumor 1 and tumor 2 and enhanced differentiation of PD-1+ TCF-1+ T cells into TIM-3+ cells compared to either monotherapy alone (Fig. 3h–l). The gene discussed is PDCD1; the disease is neoplasm.